Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Sarcoma, Ewing 2Sarcoma 2Ovarian Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Recurrence 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Hemangiosarcoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoid Tumor 1Adenoma, Islet Cell 1

Interventions

Everolimus 5Temozolomide 4sargramostim 2montanide ISA 51 2lutetium Lu 177 dotatate 2incomplete Freund's adjuvant 2Sunitinib 2Specimen Handling 2Sorafenib 2Octreotide 2Magnetic Resonance Spectroscopy 2Leucovorin 2Fluorouracil 2Cytoreduction Surgical Procedures 2Colony-Stimulating Factors 2Bevacizumab 2surufatinib 1recombinant interferon alpha 2b-like protein 1pentetreotide 1pasireotide 1nimotuzumab 1ibrutinib 1ganitumab 1gallium Ga 68 dotatate 1fludarabine phosphate 1cabozantinib 1atezolizumab 1abemaciclib 1Wound Healing 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenoma, Islet Cell × ganitumab × Clear all
NCT01024387 2018-03-08

AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 2 Completed
60 enrolled 7 charts
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡